These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21985578)

  • 1. Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T cell responses and confers protective antitumor immunity.
    Porchia BF; Diniz MO; Cariri FA; Santana VC; Amorim JH; Balan A; Braga CJ; Ferreira LC
    Mol Pharm; 2011 Dec; 8(6):2320-30. PubMed ID: 21985578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
    Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
    Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.
    Diniz MO; Lasaro MO; Ertl HC; Ferreira LC
    Clin Vaccine Immunol; 2010 Oct; 17(10):1576-83. PubMed ID: 20739505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model.
    Sin JI
    Vaccine; 2011 May; 29(24):4125-31. PubMed ID: 21496466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
    Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.
    Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM
    Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors.
    Porchia BFMM; Moreno ACR; Ramos RN; Diniz MO; de Andrade LHTM; Rosa DS; Barbuto JAM; Boscardin SB; Ferreira LCS
    Mol Cancer Ther; 2017 Sep; 16(9):1922-1933. PubMed ID: 28522585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.
    Sin JI; Kim JJ; Arnold RL; Shroff KE; McCallus D; Pachuk C; McElhiney SP; Wolf MW; Pompa-de Bruin SJ; Higgins TJ; Ciccarelli RB; Weiner DB
    J Immunol; 1999 Mar; 162(5):2912-21. PubMed ID: 10072541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
    Chen CA; Chang MC; Sun WZ; Chen YL; Chiang YC; Hsieh CY; Chen SM; Hsiao PN; Cheng WF
    Gene Ther; 2009 Jun; 16(6):776-87. PubMed ID: 19357714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model.
    Silva JR; Sales NS; Silva MO; Aps LRMM; Moreno ACR; Rodrigues EG; Ferreira LCS; Diniz MO
    Cancer Immunol Immunother; 2019 May; 68(5):753-763. PubMed ID: 30806747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
    Frye TD; Chiou HC; Hull BE; Bigley NJ
    Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
    Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
    Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
    Di Bonito P; Grasso F; Mochi S; Petrone L; Fanales-Belasio E; Mei A; Cesolini A; Laconi G; Conrad H; Bernhard H; Dembek CJ; Cosma A; Santini SM; Lapenta C; Donati S; Muratori C; Giorgi C; Federico M
    Virology; 2009 Dec; 395(1):45-55. PubMed ID: 19800648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex virus glycoprotein D is recognized as antigen by CD4+ and CD8+ T lymphocytes from infected mice. Characterization of T cell clones.
    Johnson RM; Lancki DW; Fitch FW; Spear PG
    J Immunol; 1990 Jul; 145(2):702-10. PubMed ID: 1973187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.